Lineage Cell Therapeutics (LCTX) Expected to Announce Earnings on Thursday

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) will likely be posting its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect Lineage Cell Therapeutics to post earnings of ($0.02) per share and revenue of $2.2950 million for the quarter. Investors may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Thursday, November 6, 2025 at 4:30 PM ET.

Lineage Cell Therapeutics Trading Down 4.8%

Shares of NYSEAMERICAN:LCTX traded down $0.10 on Tuesday, reaching $1.87. 1,966,925 shares of the company’s stock were exchanged, compared to its average volume of 1,866,356. The company has a fifty day moving average of $1.55 and a 200-day moving average of $1.08. Lineage Cell Therapeutics has a twelve month low of $0.37 and a twelve month high of $2.09. The company has a market capitalization of $425.89 million, a price-to-earnings ratio of -10.36 and a beta of 1.77.

Institutional Trading of Lineage Cell Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Hudson Bay Capital Management LP bought a new stake in shares of Lineage Cell Therapeutics during the 2nd quarter worth approximately $44,000. Brevan Howard Capital Management LP bought a new stake in shares of Lineage Cell Therapeutics during the 2nd quarter worth approximately $281,000. Raymond James Financial Inc. lifted its holdings in shares of Lineage Cell Therapeutics by 136.2% during the 2nd quarter. Raymond James Financial Inc. now owns 69,380 shares of the company’s stock worth $63,000 after acquiring an additional 40,009 shares during the period. Qube Research & Technologies Ltd bought a new stake in shares of Lineage Cell Therapeutics during the 2nd quarter worth approximately $35,000. Finally, WINTON GROUP Ltd bought a new stake in shares of Lineage Cell Therapeutics during the 2nd quarter worth approximately $69,000. Institutional investors own 62.47% of the company’s stock.

Wall Street Analyst Weigh In

Separately, D. Boral Capital restated a “buy” rating and set a $2.00 target price on shares of Lineage Cell Therapeutics in a research report on Wednesday, August 27th. Four investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Lineage Cell Therapeutics presently has an average rating of “Buy” and a consensus target price of $4.25.

Lineage Cell Therapeutics Company Profile

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.